The Biggest VC Deals of Q1 2025 and What They Mean for Founders

Q1 2025 was one of the most revealing quarters for venture capital in years. Not because of the total dollars deployed — roughly $78 billion globally, up 15% from Q1 2024 — but because of where that money went. The patterns tell a clear story about what VCs believe right now, and if you're raising, you need to understand that story.

We analyzed the 10 most notable deals of the quarter across AI infrastructure, climate tech, fintech, biotech, and enterprise SaaS. Here's what happened, and more importantly, what it means if you're building a company right now.

The Mega-Deals: AI Infrastructure Dominates

Databricks — $2.4B Series J, led by Thrive Capital, at a $62B valuation. This wasn't just a fundraise — it was a statement. Databricks is building the data infrastructure layer that every AI company needs. Revenue reportedly north of $2.4B ARR with 60%+ growth. At 26x forward revenue, the market is saying data infrastructure is the picks-and-shovels play of the AI era. What it signals: infrastructure bets are getting funded at premium valuations because the upside is enormous and the moats are real.

Anthropic — $2B Series D, led by Google, at a $18B valuation. The AI model race continued with Anthropic adding another massive round to its war chest. With Claude competing directly with GPT-4, the bet is that the market for foundation models is big enough for multiple winners — at least for now. What it signals: the foundation model layer is winner-take-most, not winner-take-all, and strategic investors (Google, Amazon) are willing to pay up for alignment with their cloud platforms.

Scale AI — $1.3B Series F, led by Accel, at a $14B valuation. Data labeling and AI evaluation might sound boring. It's not. Scale is the company that makes AI systems actually work by providing the training data, evaluation frameworks, and safety testing infrastructure. Revenue reportedly crossed $750M. What it signals: the AI supply chain is investable at every layer, not just the sexy model layer.

Climate Tech: No Longer ESG Theater

Form Energy — $800M Series F, led by T. Rowe Price, at a $4B+ valuation. Iron-air batteries that store energy for 100+ hours at a fraction of lithium-ion costs. This isn't a science project anymore — Form Energy broke ground on its first manufacturing facility in West Virginia. The grid storage market could be worth $500B+ by 2040. What it signals: climate tech is graduating from lab-stage to deployment-stage, and growth investors are now willing to fund the scaling phase.

Twelve — $645M Series C, led by Prelude Ventures and DCVC. Carbon transformation — taking CO2 from the air and turning it into jet fuel, chemicals, and materials. They secured a contract with the US Air Force and broke ground on a commercial-scale plant. What it signals: carbon capture is becoming a real business, not just a regulatory compliance play. The unit economics are getting there.

Fintech: Consolidation Mode

Stripe — $1.1B secondary offering at a $91B valuation. Not a primary fundraise — this was existing shareholders selling to new investors, notably sovereign wealth funds and pension funds. Stripe processes over $1 trillion in annual payments. The secondary signals pre-IPO positioning. What it signals: fintech infrastructure is mature and generating massive revenue. The valuations reflect real fundamentals, not hype.

Ramp — $300M Series D, led by Thrive Capital, at a $13B valuation. Corporate expense management is a category Ramp is redefining with AI-powered automation. Revenue reportedly growing 100%+ year-over-year, crossing $400M ARR. What it signals: B2B fintech is where the durable fintech value is being created. Consumer fintech is struggling; enterprise fintech is thriving.

Biotech: The Comeback Quarter

Recursion Pharmaceuticals — $500M crossover round at a $9B valuation. AI-driven drug discovery hit an inflection point in Q1 2025. Recursion's platform, which uses machine learning to identify drug candidates, delivered three candidates into Phase 2 trials. The round was led by crossover funds betting on the IPO trajectory. What it signals: AI-bio convergence is producing real clinical results, not just papers.

Xaira Therapeutics — $1B Series A, led by ARCH Venture Partners and Foresite Capital. A billion-dollar Series A. In biotech. Founded by former Illumina CEO Jay Flatley and backed by some of the biggest names in life science investing. Xaira is applying generative AI to protein design and drug development. What it signals: when the founding team is elite and the technology is transformative, VCs will write very, very large early-stage checks.

Enterprise SaaS: AI-Native Wins

Glean — $260M Series E, led by Kleiner Perkins, at a $4.6B valuation. AI-powered enterprise search is replacing the terrible search experience inside most companies. Glean's ARR reportedly crossed $200M, growing 3x year-over-year. What it signals: the enterprise AI application layer is maturing fast. Companies aren't just experimenting with AI — they're buying it at scale, and the category leaders are pulling away.

The Big Trends: What These Deals Tell Us

AI still dominates everything. Roughly 62% of mega-rounds (deals over $100M) in Q1 2025 had an AI component. But it's shifted from pure foundation models to infrastructure, applications, and vertical AI. The "thin wrapper around GPT" era is dead. Investors want companies with proprietary data, defensible workflows, or deep domain expertise.

Climate tech is real now. Climate tech VC funding hit $12B in Q1 2025, up 40% from Q1 2024. More importantly, the deals are shifting from early-stage R&D to growth-stage deployment. This means climate tech is moving from "interesting science" to "investable business." The companies getting funded have real revenue, real customers, and real manufacturing plans.

Fintech is consolidating. Deal count in fintech dropped 25% from Q1 2024, but total capital deployed rose 10%. Translation: fewer companies are getting funded, but the winners are getting bigger checks. The era of easy fintech fundraising is over. If you're building in fintech today, you need a differentiated wedge, not just another banking-as-a-service wrapper.

Biotech is back. After a brutal 2022-2023, biotech VC bounced back with a 35% increase in deal value in Q1 2025. The AI-bio intersection is the hottest sub-sector, with AI-driven drug discovery companies attracting the lion's share. If you're in bio and not incorporating AI/ML into your platform, you're going to have a harder time fundraising.

What This Means If You're Raising Right Now

If you're fundraising in 2025, here's the honest assessment based on Q1 data.

The easiest sectors to raise in: AI infrastructure, vertical AI applications (healthcare, legal, finance), climate tech with clear deployment paths, and B2B software with AI-native workflows. These sectors have the most active investors and the highest willingness to pay premium valuations.

The hardest sectors to raise in: Consumer social, general-purpose SaaS without AI differentiation, crypto (still in the penalty box with many VCs), and hardware without a clear software/data play. These aren't impossible — they're just playing on hard mode.

The stage breakdown matters: Pre-seed and seed remain relatively accessible, with deal count up 8% in Q1. Series A is still the hardest round to raise — the "Series A gap" widened in 2024 and hasn't closed. Series B+ is available if your metrics are strong, but VCs are demanding 3x+ year-over-year growth and a clear path to profitability, not just growth for growth's sake.

Where the dry powder is: VCs are sitting on an estimated $311B in undeployed capital as of Q1 2025. The money is there. But it's concentrated among the top 50 firms, and those firms are being more selective than ever. Having a strong narrative, clear metrics, and the right intros matters more than it did during the ZIRP era.

Want to track deals as they happen? Check out the VC Beast deal database for real-time funding data, and subscribe to our newsletter for weekly analysis of the deals that matter most to founders.